Innovations in Gastrointestinal Care
Gastrointestinal (GI) tract diseases and disorders are very common. During the last decade, Helicobacter pylori-induced gastritis and ulcer, rotaviral diarrhea, and obesity/metabolic syndrome are the 3 most studied subjects by medical researchers and scientists.
Helicobacter pylori-induced gastritis and ulcer.
Helicobacter pylori (H. pylori) infects about half of the world population and is an important causative agent of chronic gastritis and peptic ulcer diseases. Chronic infection by H. pylori is also associated with the development of gastric adenocarcinoma, one of the most common types of cancer in humans. This bacterium produces a large amount of urease enzyme which is bound on its surface. The enzyme, which serves as an important virulent factor of H. pylori, degrades urea in foods to form NH3, and this reaction changes local environment in the stomach from acidic (pH 2-3) to neutral side (pH 7). Various researches have reported that IgY can inactivate urease, block the adherence of H. pylori to the gastric mucosa and inhibit its growth in the stomach. A number of clinical trials have shown that IgY against urease is highly effective in controlling H. pylori level in the stomach and preventing gastritis¹.
Rotavirus is the commonest cause of severe dehydrating diarrhea among children worldwide, killing up to 600,000 children annually. While the use of vaccines has been limited in developing countries due to high cost, preventing dehydration by providing fluids and salts is the only supportive treatment that is available. Recently, the research group at IRIG in Japan has successfully developed a new IgY preparation which exhibited multi-serotypic cross neutralization in vitro and significant reduction in principal outcomes of diarrhea when used in diarrheal pediatric patients².
Obesity and metabolic syndrome.
Globally, more than 1 billion adults are overweight and at least 300 million of them are clinically obese. Metablolic syndrome (MS) is one of the major complication of obesity. One-quarter of the world’ s adult population suffers from MS. Controlling lipid absorption from the gut and fat accumulation inside the body is important to prevent MS and obesity. Among MS prevention measures, natural pancreatic lipase inhibitors have become more and more popular due to their safety. Recently, the research group at IRIG, Japan, has successfully developed a novel IgY which inhibits human lipase activity in the gut and reduces absorption of triglyceride into blood³.
Rahman Sofiqur et al. Oral passive IgY-based immunotherapeutics, a novel solution for prevention and treatment of alimentary tract diseases. Human Vaccines & Immunotherapeutics, 9:4 (1-10), 2013.
Rahman Sofiqur et al. Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. Vaccine, 30: 4661- 69, 2012.
Hirose M et al. Anti-obesity activity of hen egg anti-lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor. Nutrition and Metabolism 10:70, 2013
Ovalgen® is a natural egg-product containing immunoglobulins (IgY). It is ideally suited for combining with many different products such as health foods, functional foods or cosmetics. Already today, Ovalgen® is being applied by large food and cosmetic manufacturers, who use it to successfully promote their products.
Ovalgen® HP helps strengthening gut immune system and resistance against pathogens in our stomach. Thus it supports and promotes a healthy stomach.
In Japan Ovalgen HP is used in yogurts, tablets and in the form of capsules by large food companies.
Ovalgen® RV was developed to enhance the gut immunity in young children and as a supportive preventive and therapeutic supplement in case of gastrointestinal disorders. This product is being used in infant formulas and milk powder products.